Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy

Journal of Infectious Diseases

Volumn 173, Issue 6, 1996, Pages 1354-1366

  Schooley, Robert T ^a   Ramirez Ronda, Carlos ^c   Lange, Joep M A ^c   Cooper, David A ^c   Lavelle, James ^c   Lefkowitz, Lewis ^c   Moore, Mark ^c   Larder, Brendan A ^c   Clair, Marty St ^c   Mulder, Jan Willem ^c   McKinnis, Ray ^c   Pennington, Kevin N ^b   Richard Harrigan, P ^c   Kinghorn, Lan ^c   Steel, Helen ^c   Rooney, James F ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b MAYO CLINIC   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; PHYTOHEMAGGLUTININ; PLACEBO; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG RESISTANCE; FEMALE; GASTROINTESTINAL TOXICITY; HEPATOBILIARY DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 9444290697     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.6.1354     Document Type: Article

References (14)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N EngI J Med 1987;317:185-91.
2. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:192-7.
3. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind, placebo-controlled trial. Ann Intern Med 1990;112:727-37.
4. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322:941-9.
5. Merigan TC, Skowron G, Bozzette SA, et al. Circulating p24 antigen levels and responses to zalcitabine in human immunodeficiency virus (HIV) infections. A phase I and II study. Ann Intern Med 1989;110:189-94.
6. Cooper DA, Gatell JM, Kroon S, et al. Zidovudine in persons with asymptomatic HIV infection and CD4 cell counts greater than 400 per cubic millimeter. N Engl J Med 1993;329:297-303.
7. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med 1992;326:437-43.
8. Mulder JW, Cooper DA, Mathiesen L, et al. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized double-blind placebo-controlled study. AIDS 1994;8:313-21.
9. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free individuals. Lancet 1994;343:871-81.
10. Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994;272:437-42.
11. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science 1989;243:1731-4.
12. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high level resistance to zidovudine (AZT). Science 1989;246:1155-8.
13. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immun Defic Syndr 1990;3:743-6.
14. D'Aquila RT, Johnson VA, Wells SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995;122:401-8.